Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hoth Therapeutics Inc HOTH

Healthcare
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s... see more

Recent & Breaking News (NDAQ:HOTH)

Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline

PR Newswire June 3, 2020

Hoth Therapeutics Announces Closing of Public Offering of Common Stock

PR Newswire May 27, 2020

Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board

PR Newswire May 22, 2020

Hoth Announces Pricing of Public Offering of Shares of Common Stock

PR Newswire May 21, 2020

Hoth Announces Proposed Public Offering of Common Stock

PR Newswire May 21, 2020

Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic

PR Newswire May 20, 2020

Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment

PR Newswire May 18, 2020

Hoth Therapeutics Expands Partnership with Zylö Therapeutics, Inc.

PR Newswire May 5, 2020

Voltron Therapeutics, Inc. Announces Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine

PR Newswire April 24, 2020

Hoth Therapeutics, Inc., Voltron Therapeutics, Inc., & HaloVax Announce Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine

PR Newswire April 24, 2020

REMINDER: Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate

PR Newswire April 23, 2020

Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate

PR Newswire April 22, 2020

Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study

PR Newswire April 21, 2020

Hoth Therapeutics Announces Additions to its Board of Directors

PR Newswire April 17, 2020

Dr. Mark Poznansky Co-Creator of VaxCelerate Appeared on MSNBC to Discuss COVID-19 Vaccines

PR Newswire April 15, 2020

Hoth Therapeutics Commences Next Phase of VNLG-152 Study

PR Newswire April 9, 2020

Hoth Update on HaloVax Partnership Vaccine to Fight COVID-19 with Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH)

PR Newswire April 2, 2020

Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals, Inc. to License VNLG-152 for Treatment of Dermatological Diseases

PR Newswire March 30, 2020

HaloVax(TM) Announces Agreement with Hoth Therapeutics to Joint Develop a Self-Assembling Vaccine (SAV) to Protect Patients at Risk of Coronavirus (COVID-19) Infection

PR Newswire March 27, 2020

Emerging Markets Report: Hoth Therapeutics is Working on a Potential Coronavirus Vaccine (COVID-19)

GlobeNewswire March 24, 2020